In Cancer Biology,
Context Matters

Uncover immunotherapy biomarkers by visualizing the tumor microenvironment in context

Unmet Need in Cancer Immunotherapy

Despite the progress we’ve made in cancer immunotherapy, response rates continue to remain in the 20 to 30% range. There’s a need for biomarkers that can accurately predict response to treatment.

clinical-illustration-480x435

Understanding Cancer-Immune Biology

Immunotherapy treatments rely on the activation of the patient’s immune system to fight and kill tumor cells. The key to understanding more about tumor-immune biology lies in studying the complexity of the tumor microenvironment.

Transforming Your Approach to Cancer Biomarker Discovery

Multiplex immunofluorescence (mIF) enables the discovery of biomarker signatures from a single FFPE tissue section, while preserving the spatial context of the tumor microenvironment.

icon-Visualize

Visualize

See how cells organize and interact in the tumor microenvironment
icon-Quantify

Quantify

Shift the paradigm from subjective IHC measurements to quantitative, reproducible mIF
icon-Predict

Predict

Reliably predict treatment response and disease progression through novel biomarker signatures

Spatial Phenotypic Signatures - Predicting
Immunotherapy Response

A New Biomarker Class in the Tumor Microenvironment
Spatial Phenotypic Signatures (SPS) measure the
Interactions and Cell Densities
Of Tumor and Immune Cells
in the tumor microenvironment.
Measuring Spatial Phenotypic Signatures
Spatial Phenotypic Signatures can be
accurately measured with
MULTIPLEX
IMMUNOFLUORESCENCE (mIF)
Better Predictive Capabilities and Reproducibility
A multi-institutional study found that mIF had
Higher Predictive Accuracy
than PD-L1 IHC and genomic biomarkers.
Saving Precious Time and Tissue Samples
With multiplex immunofluorescence you can:
Analyze dozens of cell phenotypes and their spatial interactions from a
SINGLE FFPE TISSUE SECTION
Process
25 to 30 SAMPLES PER DAY
Slider

Oncology Experts Discover Spatial Phenotypic
Signatures with mIF

Spatial Phenotypic Signatures, measured by mIF, outperform PD-L1 IHC and genomic biomarkers, in predicting immunotherapy response
Johns Hopkins Pioneers New mIF-based Biomarker Platform

Read Press Release >

UCSF Implements mIF to Discover Biomarkers in I-SPY Trial

Read Press Release >

Immuno-Oncology KOLs Explain Why Context Matters in Tumor Biology

Watch Expert Opinion >

In the translational research group, we are developing completely new types of tissue testing and imaging technology. These include the Phenoptics™ mIF workflow which we have implemented for our ImmunoProfile project at DFCI/BWH. This multi-omics approach captures far more immunological information within a tumor biopsy sample than has been accessible before.

Dr. Scott Rodig
Pathologist, Brigham & Women’s Hospital
Director, Center for Immuno-Oncology Tissue Biomarker Laboratory
Dana-Farber Cancer Institute
Professor Pathology, Harvard Medical School

Standardization Efforts

The value of Spatial Phenotypic Signatures in translational and clinical research relies on a standardized and reproducible workflow.

MITRE: First Multi-Site mIF Standardization Study

Validating mIF Panels for PD-L1 Testing

Bringing mIF to the Clinic

What's New

Immune Biomarker Trailblazer at Columbia University Validates mIF Workflow for Melanoma

Johns Hopkins Astronomy and Pathology Experts Come Together to Tackle Cancer Biology

Queen's University Offers Comprehensive Opal Multiplex Optimization and Validation Protocols